Compare FBIN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIN | LEGN |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.9B |
| IPO Year | 2011 | 2020 |
| Metric | FBIN | LEGN |
|---|---|---|
| Price | $42.55 | $20.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | $54.60 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 2.1M | 1.8M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $4,463,200,000.00 | N/A |
| Revenue This Year | $2.68 | $42.68 |
| Revenue Next Year | $3.60 | $30.52 |
| P/E Ratio | $4,311.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.34 | $16.24 |
| 52 Week High | $64.84 | $37.50 |
| Indicator | FBIN | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 45.52 |
| Support Level | $40.36 | $19.96 |
| Resistance Level | $42.63 | $21.97 |
| Average True Range (ATR) | 1.30 | 0.98 |
| MACD | -0.27 | 0.18 |
| Stochastic Oscillator | 14.52 | 28.13 |
Fortune Brands is a US-based homebuilding products company that sells building-related products serving R&R and new construction markets. The company operates in three segments: water, outdoors, and security. Water innovation, including plumbing fixtures and faucets, accounts for around 55% of total sales and features brands such as Moen, House of Rohl, and Aqualisa. The outdoors segment includes decking, railing, and doors and makes up 30% of total sales, featuring brands such as Larson, Fiberon, and Therma-Tru. The security segment, which includes smart residential padlocks, accounts for the remaining 15% of sales and features brands such as MasterLock, SentrySafe, Yale, and AmericanLock.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.